Quetiapine augmentation of prolonged exposure therapy in veterans with PTSD and a history of mild traumatic brain injury: design and methodology of a pilot study

Muhammad R Baig, Robert D Beck, Jennifer L Wilson, Jennifer A Lemmer, Adeel Meraj, Eric C Meyer, Jim Mintz, Alan L Peterson, John D Roache, Muhammad R Baig, Robert D Beck, Jennifer L Wilson, Jennifer A Lemmer, Adeel Meraj, Eric C Meyer, Jim Mintz, Alan L Peterson, John D Roache

Abstract

Background: Selective serotonergic reuptake inhibitors (SSRIs) are first-line pharmacologic treatments for patients with posttraumatic stress disorder (PTSD), but must be given over extended period of time before the onset of action. The use of SSRIs in PTSD patients with mild traumatic brain injury (mTBI) is problematic since SSRIs could exacerbate post-concussion syndrome (PCS) symptoms. VA/DOD guidelines identify trauma-focused psychotherapy as the best evidence-based treatment for PTSD, but overall effectiveness is limited by reduced levels of patient engagement and retention. A previous study from this research group suggested that quetiapine monotherapy, but not risperidone or valproate, could increase engagement in trauma-focused psychotherapy.

Methods: We report the study protocol of a pilot study funded under the South-Central Mental Illness Research, Education, and Clinical Center pilot study program from the U.S. Department of Veterans Affairs. This randomized, open-label study was designed to evaluate the feasibility of completing a randomized trial of quetiapine vs. treatment as usual to promote patient engagement in PTSD patients with a history of mTBI.

Discussion: We expect that the success of this ongoing study should provide us with the preliminary data necessary to design a full-scale randomized trial. Positive efficacy results in a full- scale trial should inform new VA guidelines for clinical practice by showing that quetiapine-related improvements in patient engagement and retention may be the most effective approach to assure that VA resources achieve the best possible outcome for veterans.

Trial registration: NCT04280965 .

Keywords: Mild traumatic brain injury; Posttraumatic stress disorder; Quetiapine; Trauma-focused psychotherapy; Veterans.

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Study design: RCTs for Quetiapine vs. TAU treatment. TAU. Treatment as usual

References

    1. Lindquist LK, Love HC, Elbogen EB. Traumatic brain injury in Iraq and Afghanistan veterans: new results from a national random sample study. J Neuropsychiatry Clin Neurosci. 2017;29(3):254–259. doi: 10.1176/appi.neuropsych.16050100.
    1. Carlson KF, Nelson D, Orazem RJ, Nugent S, Cifu DX, Sayer NA. Psychiatric diagnoses among Iraq and Afghanistan war veterans screened for deployment-related traumatic brain injury. J Trauma Stress. 2010;23(1):17–24. doi: 10.1002/jts.20483.
    1. McGlinchey RE, Milberg WP, Fonda JR, Fortier CB. A methodology for assessing deployment trauma and its consequences in OEF/OIF/OND veterans: the TRACTS longitudinal prospective cohort study. Int J Methods Psychiatr Res. 2017;26:e1556. doi: 10.1002/mpr.1556.
    1. Swanson TM, Isaacson BM, Cyborski CM, French LM, Tsao JW, Pasquina PF. Traumatic brain injury incidence, clinical overview, and policies in the US military health system since 2000. Public Health Rep. 2017;132(2):251–259. doi: 10.1177/0033354916687748.
    1. Kraus J, Schaffer K, Ayers K, Stenehjem J, Shen H, Afifi AA. Physical complaints, medical service use, and social and employment changes following mild traumatic brain injury: a 6-month longitudinal study. J Head Trauma Rehabil. 2005;20(3):239–256. doi: 10.1097/00001199-200505000-00007.
    1. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282(15):1458–1465. doi: 10.1001/jama.282.15.1458.
    1. Duff J, Walker K, Omari A. Translating venous thromboembolism (VTE) prevention evidence into practice: a multidisciplinary evidence implementation project. Worldviews Evid-Based Nurs. 2011;8(1):30–39. doi: 10.1111/j.1741-6787.2010.00209.x.
    1. Pelissier C, Fort E, Fontana L, Charbotel B, Hours M. Factors associated with non-return to work in the severely injured victims 3 years after a road accident: a prospective study. Accid Ann Prev. 2017;106:411–419. doi: 10.1016/j.aap.2017.06.020.
    1. Dold M, Bartova L, Kautzky A, Souery D, Mendlewicz J, Serretti A, et al. The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes - results from a cross-sectional European multicenter study. Eur Neuropsychopharmacol. 2017;27(7):625–632. doi: 10.1016/j.euroneuro.2017.05.004.
    1. Carroll LJ, Cassidy JD, Peloso PM, Borg J, von Holst H, Holm L, et al. Prognosis for mild traumatic brain injury: results of the WHO collaborating Centre task force on mild traumatic brain injury. J Rehab Med. 2004;(43 Suppl):84–105.
    1. Ishibe N, Wlordarczyk RC, Fulco C. Overview of the institute of medicine's committee search strategy and review process for gulf war and health: long-term consequences of traumatic brain injury. J Head Trauma Rehabil. 2009;24(6):424–429. doi: 10.1097/HTR.0b013e3181c13426.
    1. Iverson GL, Lange RT. Examination of “postconcussion-like” symptoms in a healthy sample. Appl Neuropsychol. 2003;10(3):137–144. doi: 10.1207/S15324826AN1003_02.
    1. Goodson JT, Lefkowitz CM, Helstrom AW, Gawrysiak MJ. Outcomes of prolonged exposure therapy for veterans with posttraumatic stress disorder. J Trauma Stress. 2013;26(4):419–425. doi: 10.1002/jts.21830.
    1. Foa EB, McLean CP, Zang Y, Rosenfield D, Yadin E, Yarvis JS, et al. Effect of prolonged exposure therapy delivered over 2 weeks vs 8 weeks vs present-centered therapy on PTSD symptom severity in military personnel: a randomized clinical trial. JAMA. 2018;319(4):354–364. doi: 10.1001/jama.2017.21242.
    1. Powers MB, Halpern JM, Ferenschak MP, Gillihan SJ, Foa EB. A meta-analytic review of prolonged exposure for posttraumatic stress disorder. Clin Psychol Rev. 2010;30(6):635–641. doi: 10.1016/j.cpr.2010.04.007.
    1. Peterson AL, Foa EB, Riggs DS. Prolonged exposure therapy. In: Bret AM, Walter EP, editors. Treating PTSD in military personnel: a clinical handbook. 2. New York: Guilford; 2019. pp. 46–62.
    1. Sripada RK, Rauch SA, Tuerk PW, Smith E, Defever AM, Mayer RA, et al. Mild traumatic brain injury and treatment response in prolonged exposure for PTSD. J Trauma Stress. 2013;26(3):369–375. doi: 10.1002/jts.21813.
    1. Mikolic A, Polinder S, Retel Helmrich IRA, Haagsma JA, Cnossen MC. Treatment for posttraumatic stress disorder in patients with a history of traumatic brain injury: a systematic review. Clin Psychol Rev. 2019;73:101776. doi: 10.1016/j.cpr.2019.101776.
    1. Hundt NE, Ecker AH, Thompson K, Helm A, Smith TL, Stanley MA, et al. “It didn't fit for me:” a qualitative examination of dropout from prolonged exposure and cognitive processing therapy in veterans. Psychol Serv. 2018. 10.1037/ser0000316.
    1. Miles SR, Smith TL, Maieritsch KP, Ahearn EP. Fear of losing emotional control is associated with cognitive processing therapy outcomes in U.S. veterans of Afghanistan and Iraq. J Trauma Stress. 2015;28(5):475–479. doi: 10.1002/jts.22036.
    1. Jaeger JA, Echiverri A, Zoellner LA, Post L, Feeny NC. Factors associated with choice of exposure therapy for PTSD. Int J Behav Consult Ther. 2009;5(3–4):294–310.
    1. Tarrier N, Pilgrim H, Sommerfield C, Faragher B, Reynolds M, Graham E, et al. A randomized trial of cognitive therapy and imaginal exposure in the treatment of chronic posttraumatic stress disorder. J Consult Clin Psychol. 1999;67(1):13–18. doi: 10.1037/0022-006X.67.1.13.
    1. Belleau EL, Chin EG, Wanklyn SG, Zambrano-Vazquez L, Schumacher JA, Coffey SF. Pre-treatment predictors of dropout from prolonged exposure therapy in patients with chronic posttraumatic stress disorder and comorbid substance use disorders. Behav Res Ther. 2017;91:43–50. doi: 10.1016/j.brat.2017.01.011.
    1. Steenkamp MM, Litz BT, Hoge CW, Marmar CR. Psychotherapy for military-related PTSD: a review of randomized clinical trials. JAMA. 2015;314(5):489–500. doi: 10.1001/jama.2015.8370.
    1. Jeffreys MD, Reinfeld C, Nair PV, Garcia HA, Mata-Galan E, Rentz TO. Evaluating treatment of posttraumatic stress disorder with cognitive processing therapy and prolonged exposure therapy in a VHA specialty clinic. J Anxiety Disord. 2014;28(1):108–114. doi: 10.1016/j.janxdis.2013.04.010.
    1. Imel ZE, Laska K, Jakupcak M, Simpson TL. Meta-analysis of dropout in treatments for posttraumatic stress disorder. J Consult Clin Psychol. 2013;81(3):394–404. doi: 10.1037/a0031474.
    1. Krystal JH, Davis LL, Neylan TC, Raskind MA, Schnurr PP, Stein MB, et al. It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: a consensus statement of the PTSD psychopharmacology working group. Biol Psychiatry. 2017;82:e51–e59. doi: 10.1016/j.biopsych.2017.03.007.
    1. Asnis GM, Kohn SR, Henderson M, Brown NL. SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations. Drugs. 2004;64(4):383–404. doi: 10.2165/00003495-200464040-00004.
    1. Raskind MA, Thompson C, Petrie EC, Dobie DJ, Rein RJ, Hoff DJ, et al. Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. J Clin Psychiatry. 2002;63(7):565–568. doi: 10.4088/JCP.v63n0705.
    1. Peskind ER, Bonner LT, Hoff DJ, Raskind MA. Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder. J Geriatr Psychiatry Neurol. 2003;16(3):165–171. doi: 10.1177/0891988703256050.
    1. Raskind MA, Peskind ER, Kanter ED, Petrie EC, Radant A, Thompson CE, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry. 2003;160(2):371–373. doi: 10.1176/appi.ajp.160.2.371.
    1. Raskind MA, Peskind ER, Chow B, Harris C, Davis-Karim A, Holmes HA, et al. Trial of prazosin for post-traumatic stress disorder in military veterans. N Engl J Med. 2018;378(6):507–517. doi: 10.1056/NEJMoa1507598.
    1. Berger W, Mendlowicz MV, Marques-Portella C, Kinrys G, Fontenelle LF, Marmar CR, et al. Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review. Prog Neuro-Psychopharmacol Biol Psychiatry. 2009;33(2):169–180. doi: 10.1016/j.pnpbp.2008.12.004.
    1. Davidson J, Baldwin D, Stein DJ, Kuper E, Benattia I, Ahmed S, et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry. 2006;63(10):1158–1165. doi: 10.1001/archpsyc.63.10.1158.
    1. Kosten TR, Frank JB, Dan E, McDougle CJ, Giller EL., Jr Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Ner Ment Dis. 1991;179(6):366–370. doi: 10.1097/00005053-199106000-00011.
    1. Friedman MJ, Marmar CR, Baker DG, Sikes CR, Farfel GM. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry. 2007;68(5):711–720. doi: 10.4088/JCP.v68n0508.
    1. Committee on the Assessment of Ongoing Efforts in the Treatment of Posttraumatic Stress Disorder, Board on the Health of Select Populations, Institute of Medicine . Treatment for posttraumatic stress disorder in military and veteran populations: final assessment. Washington (DC): National Academies Press (US); 2014.
    1. Bernardy NC, Lund BC, Alexander B, Friedman MJ. Prescribing trends in veterans with posttraumatic stress disorder. J Clin Psychiatry. 2012;73(3):297–303. doi: 10.4088/JCP.11m07311.
    1. Kaufmann CN, Orff HJ, Moore RC, Delano-Wood L, Depp CA, Schiehser DM. Psychometric characteristics of the insomnia severity index in veterans with history of traumatic brain injury. Behav Sleep Med. 2019;17(1):12–18. doi: 10.1080/15402002.2016.1266490.
    1. Mollayeva T, Thurairajah P, Burton K, Mollayeva S, Shapiro CM, Colantonio A. The Pittsburgh sleep quality index as a screening tool for sleep dysfunction in clinical and non-clinical samples: a systematic review and meta-analysis. Sleep Med Rev. 2016;25:52–73. doi: 10.1016/j.smrv.2015.01.009.
    1. Collett GA, Song K, Jaramillo CA, Potter JS, Finley EP, Pugh MJ. Prevalence of central nervous system polypharmacy and associations with overdose and suicide-related behaviors in Iraq and Afghanistan war veterans in VA care 2010-2011. Drugs Real World Outcomes. 2016;3(1):45–52. doi: 10.1007/s40801-015-0055-0.
    1. Krystal JH, Rosenheck RA, Cramer JA, Vessicchio JC, Jones KM, Vertrees JE, et al. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA. 2011;306(5):493–502. doi: 10.1001/jama.2011.1080.
    1. Davis LL, Davidson JR, Ward LC, Bartolucci A, Bowden CL, Petty F. Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmacol. 2008;28(1):84–88. doi: 10.1097/JCP.0b013e318160f83b.
    1. Villarreal G, Hamner MB, Canive JM, Robert S, Calais LA, Durklaski V, et al. Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. Am J Psychiatry. 2016;173(12):1205–12. doi: 10.1176/appi.ajp.2016.15070967.
    1. Matsumoto Y, Morinobu S, Yamamoto S, Matsumoto T, Takei S, Fujita Y, et al. Vorinostat ameliorates impaired fear extinction possibly via the hippocampal NMDA-CaMKII pathway in an animal model of posttraumatic stress disorder. Psychopharmacology. 2013;229(1):51–62. doi: 10.1007/s00213-013-3078-9.
    1. Acheson D, Feifel D, de Wilde S, McKinney R, Lohr J, Risbrough V. The effect of intranasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample. Psychopharmacology. 2013;229(1):199–208. doi: 10.1007/s00213-013-3099-4.
    1. Popiel A, Zawadzki B, Praglowska E, Teichman Y. Prolonged exposure, paroxetine and the combination in the treatment of PTSD following a motor vehicle accident. A randomized clinical trial - the “TRAKT” study. J Behav Ther Exp Psychiatry. 2015;48:17–26. doi: 10.1016/j.jbtep.2015.01.002.
    1. Schneier FR, Neria Y, Pavlicova M, Hembree E, Suh EJ, Amsel L, et al. Combined prolonged exposure therapy and paroxetine for PTSD related to the world trade center attack: a randomized controlled trial. Am J Psychiatry. 2012;169(1):80–88. doi: 10.1176/appi.ajp.2011.11020321.
    1. Simon NM, Connor KM, Lang AJ, Rauch S, Krulewicz S, LeBeau RT, et al. Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. J Clin Psychiatry. 2008;69(3):400–405. doi: 10.4088/JCP.v69n0309.
    1. Echiverri-Cohen A, Zoellner LA, Gallop R, Feeny N, Jaeger J, Bedard-Gilligan M. Changes in temporal attention inhibition following prolonged exposure and sertraline in the treatment of PTSD. J Consult Clin Psychol. 2016;84(5):415–426. doi: 10.1037/ccp0000080.
    1. Jun JJ, Zoellner LA, Feeny NC. Sudden gains in prolonged exposure and sertraline for chronic PTSD. Depress Anxiety. 2013;30(7):607–613. doi: 10.1002/da.22119.
    1. Jerud AB, Pruitt LD, Zoellner LA, Feeny NC. The effects of prolonged exposure and sertraline on emotion regulation in individuals with posttraumatic stress disorder. Behav Res Ther. 2016;77:62–67. doi: 10.1016/j.brat.2015.12.002.
    1. Flanagan JC, Sippel LM, Wahlquist A, Moran-Santa Maria MM, Back SE. Augmenting prolonged exposure therapy for PTSD with intranasal oxytocin: a randomized, placebo-controlled pilot trial. J Psychiatr Res. 2017;98:64–69. doi: 10.1016/j.jpsychires.2017.12.014.
    1. Rauch SA, Foa EB, Furr JM, Filip JC. Imagery vividness and perceived anxious arousal in prolonged exposure treatment for PTSD. J Trauma Stress. 2004;17(6):461–465. doi: 10.1007/s10960-004-5794-8.
    1. Deacon B, Kemp JJ, Dixon LJ, Sy JT, Farrell NR, Zhang AR. Maximizing the efficacy of interoceptive exposure by optimizing inhibitory learning: a randomized controlled trial. Behav Res Ther. 2013;51(9):588–596. doi: 10.1016/j.brat.2013.06.006.
    1. Lund BC, Bernardy NC, Alexander B, Friedman MJ. Declining benzodiazepine use in veterans with posttraumatic stress disorder. J Clin Psychiatry. 2012;73(3):292–296. doi: 10.4088/JCP.10m06775.
    1. Viola J, Ditzler T, Batzer W, Harazin J, Adams D, Lettich L, et al. Pharmacological management of post-traumatic stress disorder: clinical summary of a five-year retrospective study, 1990-1995. M Med. 1997;162(9):616–619.
    1. Rothbaum BO, Price M, Jovanovic T, Norrholm SD, Gerardi M, Dunlop B, et al. A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan war veterans. Am J Psychiatry. 2014;171(6):640–648. doi: 10.1176/appi.ajp.2014.13121625.
    1. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS drugs. 2006;20(5):389–409. doi: 10.2165/00023210-200620050-00004.
    1. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL study group. J Clin Psychopharmacol. 1996;16(2):158–169. doi: 10.1097/00004714-199604000-00008.
    1. Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2004;6(3):213–223. doi: 10.1111/j.1399-5618.2004.00115.x.
    1. El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010;13(7):917–932. doi: 10.1017/S1461145710000015.
    1. Robert S, Hamner MB, Kose S, Ulmer HG, Deitsch SE, Lorberbaum JP. Quetiapine improves sleep disturbances in combat veterans with PTSD: sleep data from a prospective, open-label study. J Clin Psychopharmacol. 2005;25(4):387–388. doi: 10.1097/01.jcp.0000169624.37819.60.
    1. Wiegand MH, Landry F, Bruckner T, Pohl C, Vesely Z, Jahn T. Quetiapine in primary insomnia: a pilot study. Psychopharmacology. 2008;196(2):337–338. doi: 10.1007/s00213-007-0968-8.
    1. Galovski TE, Harik JM, Blain LM, Elwood L, Gloth C, Fletcher TD. Augmenting cognitive processing therapy to improve sleep impairment in PTSD: a randomized controlled trial. J Consult Clin Psychol. 2016;84(2):167–177. doi: 10.1037/ccp0000059.
    1. Cohrs S, Rodenbeck A, Guan Z, Pohlmann K, Jordan W, Meier A, et al. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology. 2004;174(3):421–429.
    1. Gedge L, Lazowski L, Murray D, Jokic R, Milev R. Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression. Neuropsychiatr Dis Treat. 2010;6:501–508.
    1. Ma L, Yang F, Zhao R, Li L, Kang X, Xiao L, et al. Quetiapine attenuates cognitive impairment and decreases seizure susceptibility possibly through promoting myelin development in a rat model of malformations of cortical development. Brain Res. 2015;1622:443–451. doi: 10.1016/j.brainres.2015.07.012.
    1. Nikiforuk A. Quetiapine ameliorates stress-induced cognitive inflexibility in rats. Neuropharmacology. 2013;64:357–364. doi: 10.1016/j.neuropharm.2012.06.042.
    1. Baig MR, Wilson JL, Lemmer JA, Beck RD, Peterson AL, Roache JD. Enhancing completion of cognitive processing therapy for posttraumatic stress disorder with quetiapine in veterans with mild traumatic brain injury: a case series. Psychiatr Q. 2019;90(2):431–445. doi: 10.1007/s11126-019-09638-z.
    1. Baig MR, Tapia RN, Meraj A, Pugh JA, Roache JD, Finley EP. Enhancing access to psychiatric care for posttraumatic stress disorder in veterans with mild traumatic brain injury through integrated services. Psychiatr Q. 2019;90940:815–827. doi: 10.1007/s11126-019-09668-7.
    1. Weathers FW, Litz BT, Keane TM, Palmieri PA, Marx BP, Schnurr PP. The PTSD checklist for DSM-5 (PCL-5): National Center for PTSD; 2013. . Accessed 21 Jul 2020.
    1. Murphy D, Ross J, Ashwick R, Armour C, Busuttil W. Exploring optimum cut-off scores to screen for probable posttraumatic stress disorder within a sample of UK treatment-seeking veterans. Eur J Psychotraumatol. 2017;8(1):1398001. doi: 10.1080/20008198.2017.1398001.
    1. Burghardt KJ, Seyoum B, Mallisho A, Burghardt PR, Kowluru RA, Yi Z. Atypical antipsychotics, insulin resistance and weight: a meta-analysis of healthy volunteer studies. Prog Neuro-Psychopharmacol Biol Psychiatry. 2018;83:55–63. doi: 10.1016/j.pnpbp.2018.01.004.
    1. Schumm JA, Gore WL, Chard KM, Meyer EC. Examination of the World Health Organization disability assessment system as a measure of disability severity among veterans receiving cognitive processing therapy. J Trauma Stress. 2017;30(6):704–709. doi: 10.1002/jts.22243.
    1. Weathers FW, Blake DD, Schnurr P. The clinician-administered PTSD scale for DSM-5 (CAPS-5) - past month. U.S.A.: National Center for PTSD; 2015.
    1. Martin JL, Song Y, Hughes J, Jouldjian S, Dzierzewski JM, Fung CH, et al. A four-session sleep intervention program improves sleep for older adult day health care participants: results of a randomized controlled trial. Sleep. 2017;40(8):zsx079. doi: 10.1093/sleep/zsx079.
    1. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613. doi: 10.1046/j.1525-1497.2001.016009606.x.
    1. Tedeschi RG, Calhoun LG. The posttraumatic growth inventory: measuring the positive legacy of trauma. J Trauma Stress. 1996;9(3):455–471. doi: 10.1002/jts.2490090305.
    1. Foa EB. Prolonged exposure therapy: past, present, and future. Depress Anxiety. 2011;28(12):1043–1047. doi: 10.1002/da.20907.
    1. Kraemer HC, Mintz J, Noda A, Tinklenberg J, Yesavage JA. Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry. 2006;63(5):484–489. doi: 10.1001/archpsyc.63.5.484.
    1. Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in clinical research. J Psychiatr Res. 2011;45(5):626–629. doi: 10.1016/j.jpsychires.2010.10.008.
    1. Hertzog MA. Considerations in determining sample size for pilot studies. Res Nurs Health. 2008;31(2):180–191. doi: 10.1002/nur.20247.
    1. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale: Erlbaum Associates; 1988.
    1. Database of privately and publicly funded clinical studies conducted around the world. National Institutes of Health, U.S.A. 2020. . Accessed 21 Jul 2020.
    1. Clinical Practice Guidelines . Managment of posttraumatic stress disorder and acute stress reaction. U.S.A: Veterans Affairs/ Department of Defence; 2017.
    1. Foa EB, Hembree EA, Rothbaum BO. Prolonged exposure therapy for PTSD: emotional processing of traumatic experiences therapist guide. New York: Oxford University Press; 2007.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren